These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32084238)

  • 21. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
    Yokoyama Y; Ramakrishnan S
    Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery.
    Tripodi AAP; Ranđelović I; Biri-Kovács B; Szeder B; Mező G; Tóvári J
    Pathol Oncol Res; 2020 Jul; 26(3):1879-1892. PubMed ID: 31820302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of (188)Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts.
    Ma W; Shao Y; Yang W; Li G; Zhang Y; Zhang M; Zuo C; Chen K; Wang J
    Tumour Biol; 2016 Jul; 37(7):9121-9. PubMed ID: 26768609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virus-Inspired Gold Nanorod-Mesoporous Silica Core-Shell Nanoparticles Integrated with tTF-EG3287 for Synergetic Tumor Photothermal Therapy and Selective Therapy for Vascular Thrombosis.
    Luo X; Xie J; Zhou Z; Ma S; Wang L; Li M; Liu J; Wang P; Li Y; Luo F; Yan J
    ACS Appl Mater Interfaces; 2021 Sep; 13(37):44013-44027. PubMed ID: 34494427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
    Schliemann C; Gerwing M; Heinzow H; Harrach S; Schwöppe C; Wildgruber M; Hansmeier AA; Angenendt L; Berdel AF; Stalmann U; Berning B; Kratz-Albers K; Middelberg-Bisping K; Wiebe S; Albring J; Wilms C; Hartmann W; Wardelmann E; Krähling T; Heindel W; Gerss J; Bormann E; Schmidt H; Lenz G; Kessler T; Mesters RM; Berdel WE
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32517329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR.
    Höink A; Persigehl T; Kwiecien R; Balthasar M; Mesters R; Berdel W; Heindel W; Bremer C; Schwöppe C
    Oncol Lett; 2019 Jan; 17(1):270-280. PubMed ID: 30655764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
    Corti A; Gasparri AM; Sacchi A; Colombo B; Monieri M; Rrapaj E; Ferreri AJM; Curnis F
    Mol Pharm; 2020 Oct; 17(10):3813-3824. PubMed ID: 32805112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
    Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q
    Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and activity evaluation of a new 5-fluorouracil prodrug containing an Asn-Gly-Arg(NO2)COOCH3 tripeptide.
    Luan Y; Jing F; Zhang J; Zou M; Wang X; Jia Y; Liu N; Mou J; Xu W
    Protein Pept Lett; 2012 Oct; 19(10):1122-31. PubMed ID: 22512656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
    Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of fusion proteins for selective occlusion of tumor vessels.
    Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
    Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13).
    Cui SX; Zhang HL; Xu WF; Qu XJ
    Eur J Pharmacol; 2014 Jul; 734():50-9. PubMed ID: 24726845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
    Berdel AF; Schwöppe C; Brand C; Harrach S; Brömmel K; Hintelmann H; Lenz G; Liersch R; Heinzow H; Schliemann C; Mesters RM; Berdel WE; Kessler T
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
    Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
    Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model.
    Norum OJ; Bruland ØS; Gorunova L; Berg K
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):878-85. PubMed ID: 19665318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
    Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
    Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
    Murphy JD; Spalding AC; Somnay YR; Markwart S; Ray ME; Hamstra DA
    Clin Cancer Res; 2009 Jan; 15(2):589-96. PubMed ID: 19147764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.